文献速递心脑血管急症

替奈普酶治疗4.5至24小时缺血性卒中:灌注影像筛选

Tenecteplase for Stroke at 4.5 to 24 Hours with Perfusion-Imaging Selection.
PubMed 文献 · N Engl J Med · 2024-02-08
一句话结论灌注影像筛选的4.5–24小时卒中患者中,替奈普酶未较安慰剂改善90天临床结局,症状性颅内出血率相近。

多中心双盲随机安慰剂对照试验纳入458例有大脑中动脉或颈内动脉闭塞及可挽救组织(灌注影像判定)的缺血性卒中患者,在最后正常时间4.5–24小时内给予替奈普酶0.25 mg/kg(最大25 mg)或安慰剂,77.3%后续接受血管内取栓。90天改良Rankin量表中位数两组均为3分,替奈普酶较安慰剂的校正共同优势比为1.13(95%CI 0.82–1.57;P=0.45)。90天死亡率替奈普酶组19.7%、安慰剂组18.2%,症状性颅内出血发生率分别为3.2%和2.3%。作者结论为替奈普酶未带来优于安慰剂的临床结局,两组症状性颅内出血发生率相近。

要点

  • 替奈普酶0.25 mg/kg(最大25 mg)用于最后正常时间4.5–24小时、灌注影像证实大脑中动脉或颈内动脉闭塞且有可挽救组织的缺血性卒中患者。
  • 90天改良Rankin量表分布:替奈普酶较安慰剂校正共同优势比1.13(95%CI 0.82–1.57;P=0.45),未达统计学显著。
  • 两组90天改良Rankin量表评分中位数均为3分;77.3%的患者后续接受了血管内取栓。
  • 安全性:90天死亡率替奈普酶组19.7% vs 安慰剂组18.2%,症状性颅内出血3.2% vs 2.3%。
  • 从最后正常时间到随机化的中位时间:替奈普酶组约12小时,安慰剂组约13小时。

适用人群与场景

  • 缺血性卒中患者,最后正常时间至随机化4.5–24小时。
  • 需有大脑中动脉或颈内动脉闭塞的证据,且灌注影像判定存在可挽救组织。
  • 本试验中77.3%的患者后续接受了血管内取栓。

诊断标准与关键阈值

  • 灌注影像判定存在可挽救组织,并有大脑中动脉或颈内动脉闭塞证据。
  • 主要结局为90天改良Rankin量表序贯评分(范围0–6分,分数越高残疾越重,6分表示死亡)。

处置流程与药物剂量

  • 替奈普酶0.25 mg/kg体重静脉给药,最大剂量25 mg,在最后正常时间4.5–24小时后给药;对照为安慰剂。
  • 试验中77.3%的患者后续接受血管内取栓。

红旗征与不能漏的情况

  • 症状性颅内出血:替奈普酶组发生率3.2%,安慰剂组2.3%。

研究设计与关键结果

  • 多中心、双盲、随机、安慰剂对照试验,纳入458例患者,替奈普酶组228例、安慰剂组230例。
  • 从最后正常时间到随机化的中位时间:替奈普酶组约12小时,安慰剂组约13小时。
  • 90天改良Rankin量表评分中位数两组均为3分。
  • 90天改良Rankin量表评分分布:替奈普酶较安慰剂校正共同优势比1.13(95%CI 0.82–1.57;P=0.45)。
  • 90天死亡率:替奈普酶组19.7% vs 安慰剂组18.2%。
  • 症状性颅内出血发生率:替奈普酶组3.2% vs 安慰剂组2.3%。

证据类型、等级与局限

  • 证据类型:多中心、双盲、随机、安慰剂对照试验(TIMELESS,ClinicalTrials.gov NCT03785678)。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 对于最后正常时间4.5–24小时、灌注影像证实大脑中动脉或颈内动脉闭塞且有可挽救组织的缺血性卒中患者,替奈普酶0.25 mg/kg(最大25 mg)未较安慰剂改善90天临床结局。
  • 作者结论:替奈普酶治疗未带来优于安慰剂的临床结局,两组症状性颅内出血发生率相近。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

BACKGROUND: Thrombolytic agents, including tenecteplase, are generally used within 4.5 hours after the onset of stroke symptoms. Information on whether tenecteplase confers benefit beyond 4.5 hours is limited.

METHODS: We conducted a multicenter, double-blind, randomized, placebo-controlled trial involving patients with ischemic stroke to compare tenecteplase (0.25 mg per kilogram of body weight, up to 25 mg) with placebo administered 4.5 to 24 hours after the time that the patient was last known to be well. Patients had to have evidence of occlusion of the middle cerebral artery or internal carotid artery and salvageable tissue as determined on perfusion imaging. The primary outcome was the ordinal score on the modified Rankin scale (range, 0 to 6, with higher scores indicating greater disability and a score of 6 indicating death) at day 90. Safety outcomes included death and symptomatic intracranial hemorrhage.

RESULTS: The trial enrolled 458 patients, 77.3% of whom subsequently underwent thrombectomy; 228 patients were assigned to receive tenecteplase, and 230 to receive placebo. The median time between the time the patient was last known to be well and randomization was approximately 12 hours in the tenecteplase group and approximately 13 hours in the placebo group. The median score on the modified Rankin scale at 90 days was 3 in each group. The adjusted common odds ratio for the distribution of scores on the modified Rankin scale at 90 days for tenecteplase as compared with placebo was 1.13 (95% confidence interval, 0.82 to 1.57; P = 0.45). In the safety population, mortality at 90 days was 19.7% in the tenecteplase group and 18.2% in the placebo group, and the incidence of symptomatic intracranial hemorrhage was 3.2% and 2.3%, respectively.

CONCLUSIONS: Tenecteplase therapy that was initiated 4.5 to 24 hours after stroke onset in patients with occlusions of the middle cerebral artery or internal carotid artery, most of whom had undergone endovascular thrombectomy, did not result in better clinical outcomes than those with placebo. The incidence of symptomatic intracerebral hemorrhage was similar in the two groups. (Funded by Genentech; TIMELESS ClinicalTrials.gov number, NCT03785678.).

来源:N Engl J Med,查看原文。版权归原作者所有。

参考来源

  1. Albers GW, Jumaa M, Purdon B, et al. Tenecteplase for Stroke at 4.5 to 24 Hours with Perfusion-Imaging Selection. N Engl J Med. 2024. PMID: 38329148. doi:10.1056/NEJMoa2310392

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。